tyzivumab
mAbexperimental
Clinical trial activity
2 trials · 6 clinical orgs · 0 marketing orgs
Phase 1
2
Phase 2
0
Phase 3
0
Phase 4
0
Earliest trial started Feb 8, 2018 (NCT03443830)
Timeline
2010s
- Jan 1, 2018
Earliest Phase 1 Sponsor(trial)
Indications
Studied for
Mechanism of action
- Zika virusINHIBITOR
Zika virus inhibitor
Chemistry & pharmacology
- Multi-specific
- No
Oral
No
Parenteral
No
Topical
No
Clinical trials
| NCT ID | Phase | Start date | Sponsor(s) |
|---|---|---|---|
| NCT03776695 | Phase 1 | Oct 9, 2018 | Duke University, Massachusetts Institute of Technology, Singapore Clinical Research Institute, Singapore General Hospital |
| NCT03443830 | Phase 1 | Feb 8, 2018 | Duke University, Massachusetts Institute of Technology, National University of Singapore, Singapore Clinical Research Institute, SingHealth Investigational Medicine Unit |
Showing 2 of 2 trials
Page 1 / 1
Organizations
Research & Development (6)
| Organization | Org type | Trials | As lead sponsor | Phases | Earliest year |
|---|---|---|---|---|---|
| Duke University | Academic/Hospital | 2 | 0 | 1 | 2018 |
| Massachusetts Institute of Technology | Academic/Hospital | 2 | 2 | 1 | 2018 |
| Singapore Clinical Research Institute | Academic/Hospital | 2 | 0 | 1 | 2018 |
| National University of Singapore | Academic/Hospital | 1 | 0 | 1 | 2018 |
| Singapore General Hospital | Academic/Hospital | 1 | 0 | 1 | 2018 |
| SingHealth Investigational Medicine Unit | For profit | 1 | 0 | 1 | 2018 |
6 organizations
Page 1 / 1